Roche’s Genentech builds autoimmune Repertoire with deal worth up to $765M
Title
Roche’s Genentech and Repertoire Immune Medicines Forge $765 Million Autoimmune Drug Discovery Partnership
Keywords
- Roche
- Genentech
- Repertoire Immune Medicines
- Autoimmune disease
- T cell-targeted therapies
- DECODE platform
- Drug discovery
- Biotech partnership
- Upfront payment
- Milestone payments
- Immunology pipeline
Key Facts
- Roche’s Genentech has entered a collaboration with Repertoire Immune Medicines to develop novel T cell-targeted therapies for autoimmune diseases, with the deal valued at up to $765 million124.
- Repertoire will lead the target discovery using its proprietary DECODE™ platform, which analyzes interactions between T cell receptors and antigenic epitopes to identify novel immune targets1.
- Genentech will be responsible for preclinical and clinical development, as well as global commercialization of the resulting therapies14.
- Repertoire is set to receive $35 million upfront, and up to $730 million in additional development, regulatory, and commercial milestone payments, alongside tiered royalties on sales1234.
- The specific autoimmune disease focus under this collaboration has not been disclosed34.
- The partnership highlights Genentech’s ongoing investment in advancing therapies for autoimmune disorders and expands its immunology and inflammation (I&I) pipeline12.
- Repertoire’s CEO indicated that the company is considering further partnerships or a potential IPO depending on market conditions4.
- The deal is part of a broader trend of major biopharma companies increasing investment in U.S. R&D and manufacturing4.
Sources:
1. https://www.repertoire.com/about/press-releases/repertoire-immune-medicines-enters-into-collaboration-and-license-agreement-with-genentech-for-the-development-of-t-cell-targeted-therapies-for-an-autoimmune-disease
2. https://www.biospace.com/business/genentech-offers-up-to-765m-in-biobucks-to-repertoire-for-i-i-drug-discovery
3. https://endpts.com/repertoire-inks-autoimmune-deal-with-genentech-as-it-eyes-a-return-to-the-clinic/
4. https://www.axios.com/pro/biotech-deals/2025/04/23/repertoire-eyes-more-licensing-deals-after-genentech-partnership